MATA NATHAN L. 4

What Happened Nathan L. Mata, Chief Scientific Officer of Belite Bio, sold a total of 1,000 American Depositary Shares (ADSs) in multiple open-market transactions on May 5, 2026, generating roughly $155,503 in proceeds. The sales were executed in six tranches: 120 @ $153.92 ($18,471); 363 @ $154.44 ($56,063); 173 @ $155.48 ($26,898); 121 @ $156.53 ($18,940); 155 @ $157.29 ($24,380); and 68 @ $158.11 ($10,751). Each ADS represents one ordinary share (footnote F1).

Key Details

• Transaction date: May 5, 2026 (filed May 6, 2026).
• Transaction type/code: Open-market sales (S).
• Total shares sold: 1,000 ADSs for total proceeds of about $155,503.
• Per-tranche details: 120 @ $153.92; 363 @ $154.44; 173 @ $155.48; 121 @ $156.53; 155 @ $157.29; 68 @ $158.11 (values above as reported).
• Footnotes: Sales were made pursuant to a Rule 10b5‑1 trading plan adopted 12/10/2025 (F2). Report includes weighted-average price groupings and ranges per footnotes F3–F7; the filer can provide exact per-price breakdowns on request.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Reported the day after the transactions (appears timely, not marked late).

Context A 10b5‑1 plan allows insiders to sell shares on a preset schedule or formula and is commonly used to avoid trading while in possession of material nonpublic information; it does not itself indicate the insider’s current view of the company. Sales (code S) are routine insider disclosures—factual reporting of disposition rather than evidence of motive.